Export 10 results:
Author Title [ Type(Desc)] Year
Filters: Author is Ledgerwood, JE  [Clear All Filters]
Journal Article
J. E. Ledgerwood, Wei, C. J., Hu, Z., Gordon, I. J., Enama, M. E., Hendel, C. S., McTamney, P. M., Pearce, M. B., Yassine, H. M., Boyington, J. C., Bailer, R., Tumpey, T. M., Koup, R. A., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 306 St, DNA Priming and Influenza Vaccine Immunogenicity: Two Phase 1 Open Label Randomised Clinical Trials, Lancet Infect Dis, vol. 11, pp. 916-924, 2011.
J. E. Ledgerwood, Bellamy, A. R., Belshe, R., Bernstein, D. I., Edupuganti, S., Patel, S. M., Renehan, P., Zajdowicz, T., Schwartz, R., Koup, R., Bailer, R. T., Yamshchikov, G. V., Enama, M. E., Sarwar, U., Larkin, B., Graham, B. S., and Team, andThe V. R. C. 70, DNA Priming for Seasonal Influenza Vaccine: a Phase 1b Double-Blind Randomized Clinical Trial, PLoS One, vol. 10, p. e0125914, 2015.
B. S. Graham, Enama, M. E., Nason, M. C., Gordon, I. J., Peel, S. A., Ledgerwood, J. E., Plummer, S. A., ,, Bailer, R. T., Roederer, M., Koup, R. A., Nabel, G. J., and Team, T. V. R. C. 008 St, DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-cell Responses After rAd5 Boost in a Randomized Clinical Trial, PLoS One, vol. 8, p. e59340, 2013.
U. N. Sarwar, Novik, L., Enama, M. E., Plummer, S. A., Koup, R. A., Nason, M. C., Bailer, R. T., McDermott, A. B., Roederer, M., ,, Ledgerwood, J. E., Graham, B. S., and Team, T. V. R. C. 015 St, Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses Despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial, PLoS One, vol. 9, p. e106240, 2014.
M. E. Enama, Ledgerwood, J. E., Novik, L., Nason, M. C., Gordon, I. J., Holman, L., Bailer, R. T., Roederer, M., Koup, R. A., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 011 St, Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (i.m.), Subcutaneous (s.c.) and Intradermal (i.d.) Administration (VRC 011), PLoS ONE, vol. 9, p. e91366, 2014.
J. E. Ledgerwood, Zephir, K., Hu, Z., Wei, C. J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 310 St, Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect, J Infect Dis, vol. 208, pp. 418-422, 2013.
J. E. Ledgerwood, Costner, P., Desai, N., Holman, L., Enama, M. E., Yamshchikov, G., Mulangu, S., Hu, Z., Andrews, C. A., Sheets, R. A., Koup, R. A., Roederer, M., Bailer, R., ,, Pau, M. G., Sullivan, N. J., Goudsmit, J., Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 205 St, A Replication Defective Recombinant Ad5 Vaccine Expressing Ebola Virus GP is Safe and Immunogenic in Healthy Adults, Vaccine, vol. 29, pp. 304-313, 2010.
U. Sarwar, Costner, P., Enama, M., Berkowitz, N., Hu, Z., Hendel, C., Sitar, S., Plummer, S., Mulangu, S., Bailer, R., Koup, R., Mascola, J., Nabel, G., Sullivan, N., Graham, B., Ledgerwood, J. E., and Team, T. V. R. C. 206 St, Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial, J Infect Dis, vol. 211, pp. 549-557, 2015.
J. E. Ledgerwood, Pierson, T. C., Hubka, S. A., Desai, N., Rucker, S., Gordon, I. J., Enama, M. E., Nelson, S., Nason, M., Gu, W., Bundrant, N., Koup, R. A., Bailer, R. T., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 303 St, A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial, J Infect Dis, vol. 203, pp. 1396-1404, 2011.